Full Text Journal Articles by
Author Donald Kufe

Advertisement

Find full text journal articles






Muc1-c in chronic inflammation and carcinogenesis;emergence as a target for cancer treatment.

Donald W Kufe,

Carcinogenesis (Carcinogenesis)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.

Keisuke Shigeta, Masanori Hasegawa, Eiji Kikuchi, Yota Yasumizu, Takeo Kosaka, Ryuichi Mizuno, Shuji Mikami, Akira Miyajima, Donald Kufe, Mototsugu Oya,

Mucin 1 C-terminal subunit (MUC1-C) has been introduced as a key regulator for acquiring drug resistance in various cancers, but the functional role of MUC1-C in urothelial carcinoma (UC) cells remains unknown. We aimed to elucidate the molecular mechanisms underlying the acquisition of cisplatin (CDDP) resistance through MUC1-C oncoprotein in ... Read more >>

Cancer Sci. (Cancer science)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.

Alexandre Detappe, Clélia Mathieu, Caining Jin, Michael P Agius, Marie-Charlotte Diringer, Vu-Long Tran, Xavier Pivot, Francois Lux, Olivier Tillement, Donald Kufe, Peter P Ghoroghchian,

PURPOSE:Heavy-metal chelators and inorganic nanoparticles (NPs) have been examined as potential radioenhancers to increase the efficacy of external beam radiation therapy for various cancers. Most of these agents have, unfortunately, displayed relatively poor pharmacokinetic properties, which limit the percentage of injected dose (%ID/g) that localizes to tumors and which shorten ... Read more >>

Int. J. Radiat. Oncol. Biol. Phys. (International journal of radiation oncology, biology, physics)
[2020, :]

Cited: 0 times

View full text PDF listing >>



MUC1-C drives stemness in progression of colitis to colorectal cancer.

Wei Li, Ning Zhang, Caining Jin, Mark D Long, Hasan Rajabi, Yota Yasumizu, Atsushi Fushimi, Nami Yamashita, Masayuki Hagiwara, Rongbin Zheng, Jin Wang, Ling Kui, Harpal Singh, Surender Kharbanda, Qiang Hu, Song Liu, Donald Kufe,

Colitis is associated with the development of colorectal cancer (CRC) by largely undefined mechanisms that are critical for understanding the link between inflammation and cancer. Intestinal stem cells (ISCs) marked by leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) expression are of importance in both the inflammatory response to colitis and ... Read more >>

JCI Insight (JCI insight)
[2020, 5(12):]

Cited: 0 times

View full text PDF listing >>



Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.

Ananth Annapragada, Andrew Sikora, Catherine Bollard, Jose Conejo-Garcia, Conrad Russell Cruz, Shadmehr Demehri, Michael Demetriou, Levon Demirdjian, Lawrence Fong, Mary Horowitz, Alan Hutson, Kathryn Kadash-Edmondson, Donald Kufe, Steven Lipkin, Song Liu, Claire McCarthy, Martin Morgan, Zachary Morris, Yang Pan, Marcelo Pasquini, Stephen Schoenberger, Eliezer Van Allen, Eduardo Vilar, Yi Xing, Wenjuan Zha, , Adekunle Odunsi,

Despite regulatory approval of several immune-based treatments for cancer in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and provide benefits for patients with cancer. As part of the Cancer Moonshot initiative, the Immuno-Oncology Translational ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(1):]

Cited: 0 times

View full text PDF listing >>



Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok K Wong, Mototsugu Oya, Donald Kufe,

An amendment to this paper has been published and can be accessed via a link at the top of the paper. ... Read more >>

Nat Commun (Nature communications)
[2020, 11(1):1095]

Cited: 0 times

View full text PDF listing >>



MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok K Wong, Mototsugu Oya, Donald Kufe,

Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and ... Read more >>

Nat Commun (Nature communications)
[2020, 11(1):338]

Cited: 0 times

View full text PDF listing >>



Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells.

Hasan Rajabi, Tsuyoshi Hata, Wei Li, Mark D Long, Qiang Hu, Song Liu, Deepak Raina, Ling Kui, Yota Yasumizu, Deli Hong, Mehmet Samur, Donald Kufe,

An amendment to this paper has been published and can be accessed via a link at the top of the paper. ... Read more >>

Oncogene (Oncogene)
[2019, 38(47):7278]

Cited: 0 times

View full text PDF listing >>



MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

Tsuyoshi Hata, Hasan Rajabi, Hidekazu Takahashi, Yota Yasumizu, Wei Li, Caining Jin, Mark D Long, Qiang Hu, Song Liu, Atsushi Fushimi, Nami Yamashita, Ling Kui, Deli Hong, Masaaki Yamamoto, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Mehmet K Samur, Donald Kufe,

The NuRD chromatin remodeling and deacetylation complex, which includes MTA1, MBD3, CHD4, and HDAC1 among other components, is of importance for development and cancer progression. The oncogenic mucin 1 (MUC1) C-terminal subunit (MUC1-C) protein activates EZH2 and BMI1 in the epigenetic reprogramming of triple-negative breast cancer (TNBC). However, there is ... Read more >>

Cancer Res. (Cancer research)
[2019, 79(22):5711-5722]

Cited: 2 times

View full text PDF listing >>



MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells.

Hasan Rajabi, Tsuyoshi Hata, Wei Li, Mark D Long, Qiang Hu, Song Liu, Deepak Raina, Ling Kui, Yota Yasumizu, Deli Hong, Mehmet Samur, Donald Kufe,

RASSF1A encodes a tumor suppressor that inhibits the RAS→RAF→MEK→ERK pathway and is one of the most frequently inactivated genes in human cancers. MUC1-C is an oncogenic effector of the cancer cell epigenome that is overexpressed in diverse carcinomas. We show here that MUC1-C represses RASSF1A expression in KRAS wild-type and ... Read more >>

Oncogene (Oncogene)
[2019, 38(47):7266-7277]

Cited: 2 times

View full text PDF listing >>



Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.

Tsuyoshi Hata, Hasan Rajabi, Masaaki Yamamoto, Caining Jin, Rehan Ahmad, Yan Zhang, Ling Kui, Wei Li, Yota Yasumizu, Deli Hong, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Hidekazu Takahashi, Mehmet Samur, Donald Kufe,

The oncogenic MUC1-C protein and the TWIST1 epithelial-mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive ... Read more >>

Mol. Cancer Ther. (Molecular cancer therapeutics)
[2019, 18(10):1744-1754]

Cited: 5 times

View full text PDF listing >>



Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.

Myrna R Nahas, Dina Stroopinsky, Jacalyn Rosenblatt, Leandra Cole, Athalia R Pyzer, Eleni Anastasiadou, Anna Sergeeva, Adam Ephraim, Abigail Washington, Shira Orr, Malgorzata McMasters, Matthew Weinstock, Salvia Jain, Rebecca K Leaf, Haider Ghiasuddin, Maryam Rahimian, Jessica Liegel, Jeffrey J Molldrem, Frank Slack, Donald Kufe, David Avigan,

Acute myeloid leukaemia (AML) is a lethal haematological malignancy characterized by an immunosuppressive milieu in the tumour microenvironment (TME) that fosters disease growth and therapeutic resistance. Hypomethylating agents (HMAs) demonstrate clinical efficacy in AML patients and exert immunomodulatory activities. In the present study, we show that guadecitabine augments both antigen ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2019, 185(4):679-690]

Cited: 2 times

View full text PDF listing >>



MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.

Masaaki Yamamoto, Caining Jin, Tsuyoshi Hata, Yota Yasumizu, Yan Zhang, Deli Hong, Takahiro Maeda, Masaaki Miyo, Masayuki Hiraki, Yozo Suzuki, Kunihiko Hinohara, Hasan Rajabi, Donald Kufe,

The oncogenic MUC1-C protein is overexpressed in triple-negative breast cancer (TNBC) cells and contributes to their epigenetic reprogramming and chemoresistance. Here we show that targeting MUC1-C genetically or pharmacologically with the GO-203 inhibitor, which blocks MUC1-C nuclear localization, induced DNA double-strand breaks and potentiated cisplatin (CDDP)-induced DNA damage and death. ... Read more >>

Cancer Res. (Cancer research)
[2019, 79(8):2031-2041]

Cited: 0 times

View full text PDF listing >>



Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.

Govind Panchamoorthy, Caining Jin, Deepak Raina, Ajit Bharti, Masaaki Yamamoto, Dennis Adeebge, Qing Zhao, Roderick Bronson, Shirley Jiang, Linjing Li, Yozo Suzuki, Ashujit Tagde, P Peter Ghoroghchian, Kwok-Kin Wong, Surender Kharbanda, Donald Kufe,

Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly overexpressed on the surface of diverse human carcinomas and is an attractive target for the development of mAb-based therapeutics. However, attempts at targeting the shed MUC1 N-terminal subunit have been unsuccessful. We report here the generation of mAb 3D1 against ... Read more >>

JCI Insight (JCI insight)
[2018, 3(12):]

Cited: 5 times

View full text PDF listing >>



Corrigendum to 'Concomitant delivery of paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy' NANO 14 (2018) 1301-1313.

Dikshi Gupta, Manoj Kumar, Priyanka Tyagi, Sumeet Kapoor, Amit Tyagi, Tarani Kanta Barman, Surender Kharbanda, Donald Kufe, Harpal Singh,

Nanomedicine (Nanomedicine : nanotechnology, biology, and medicine)
[2018, 14(7):2129]

Cited: 0 times

View full text PDF listing >>



Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer.

Masayuki Hiraki, Takahiro Maeda, Neha Mehrotra, Caining Jin, Maroof Alam, Audrey Bouillez, Tsuyoshi Hata, Ashujit Tagde, Amy Keating, Surender Kharbanda, Harpal Singh, Donald Kufe,

B-cell lymphoma 2-related protein A1 (BCL2A1) is a member of the BCL-2 family of anti-apoptotic proteins that confers resistance to treatment with anti-cancer drugs; however, there are presently no agents that target BCL2A1. The MUC1-C oncoprotein is aberrantly expressed in triple-negative breast cancer (TNBC) cells, induces the epithelial-mesenchymal transition (EMT) ... Read more >>

Signal Transduct Target Ther (Signal transduction and targeted therapy)
[2018, 3:13]

Cited: 4 times

View full text PDF listing >>



MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.

Hasan Rajabi, Masayuki Hiraki, Donald Kufe,

The PRC2 and PRC1 complexes are aberrantly expressed in human cancers and have been linked to decreases in patient survival. MUC1-C is an oncoprotein that is also overexpressed in diverse human cancers and is associated with a poor prognosis. Recent studies have supported a previously unreported function for MUC1-C in ... Read more >>

Oncogene (Oncogene)
[2018, 37(16):2079-2088]

Cited: 7 times

View full text PDF listing >>



MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.

Takahiro Maeda, Masayuki Hiraki, Caining Jin, Hasan Rajabi, Ashujit Tagde, Maroof Alam, Audrey Bouillez, Xiufeng Hu, Yozo Suzuki, Masaaki Miyo, Tsuyoshi Hata, Kunihiko Hinohara, Donald Kufe,

The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis. Here, we report that genetic or pharmacological targeting of the oncogenic MUC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells. Mechanistic investigations showed ... Read more >>

Cancer Res. (Cancer research)
[2018, 78(1):205-215]

Cited: 17 times

View full text PDF listing >>



CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice.

Keiichi Sakakibara, Takuji Sato, Donald W Kufe, Daniel D VonHoff, Takumi Kawabe,

CBP501, a calmodulin-binding peptide, is an anti-cancer drug candidate and functions as an enhancer of platinum uptake into cancer cells. Here we show that CBP501 promotes immunogenic cell death (ICD) in combination with platinum agents. CBP501 enhanced a clinically relevant low dose of cisplatin (CDDP) in vitro as evidenced by ... Read more >>

Oncotarget (Oncotarget)
[2017, 8(45):78277-78288]

Cited: 3 times

View full text PDF listing >>



Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma.

Ashujit Tagde, Tahireh Markert, Hasan Rajabi, Masayuki Hiraki, Maroof Alam, Audrey Bouillez, David Avigan, Kenneth Anderson, Donald Kufe,

The polycomb repressive complex 1 (PRC1) includes the BMI1, RING1 and RING2 proteins. BMI1 is required for survival of multiple myeloma (MM) cells. The MUC1-C oncoprotein is aberrantly expressed by MM cells, activates MYC and is also necessary for MM cell survival. The present studies show that targeting MUC1-C with ... Read more >>

Oncotarget (Oncotarget)
[2017, 8(41):69237-69249]

Cited: 2 times

View full text PDF listing >>



Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.

Salvia Jain, Abigail Washington, Rebecca Karp Leaf, Parul Bhargava, Rachael A Clark, Thomas S Kupper, Dina Stroopinsky, Athalia Pyzer, Leandra Cole, Myrna Nahas, Arie Apel, Jacalyn Rosenblatt, Jon Arnason, Donald Kufe, David Avigan,

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous neoplasm and patients with relapsed/refractory disease exhibit resistance to standard therapies. We have previously demonstrated that the Mucin 1 C-terminal subunit (MUC1-C) plays a critical role in protection from oxidative stress in CTCL cells. Targeting of MUC1-C with a pharmacologic inhibitor, GO-203, was ... Read more >>

Mol. Cancer Ther. (Molecular cancer therapeutics)
[2017, 16(10):2304-2314]

Cited: 2 times

View full text PDF listing >>



MUC1-C activates EZH2 expression and function in human cancer cells.

Hasan Rajabi, Masayuki Hiraki, Ashujit Tagde, Maroof Alam, Audrey Bouillez, Camilla L Christensen, Mehmet Samur, Kwok-Kin Wong, Donald Kufe,

The EZH2 histone methyltransferase is a member of the polycomb repressive complex 2 (PRC2) that is highly expressed in diverse human cancers and is associated with a poor prognosis. MUC1-C is an oncoprotein that is similarly overexpressed in carcinomas and has been linked to epigenetic regulation. A role for MUC1-C ... Read more >>

Sci Rep (Scientific reports)
[2017, 7(1):7481]

Cited: 12 times

View full text PDF listing >>



MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.

Audrey Bouillez, Dennis Adeegbe, Caining Jin, Xiufeng Hu, Ashujit Tagde, Maroof Alam, Hasan Rajabi, Kwok-Kin Wong, Donald Kufe,

The cancer immune microenvironment is of importance for the effectiveness of immunotherapy; however, its dysregulation is poorly understood. The MUC1-C oncoprotein is aberrantly overexpressed in non-small cell lung cancer (NSCLC) and has been linked to the induction of PD-L1. The present work investigated the effects of targeting MUC1-C in an ... Read more >>

Oncoimmunology (Oncoimmunology)
[2017, 6(9):e1338998]

Cited: 8 times

View full text PDF listing >>



MUC1-C is a target in lenalidomide resistant multiple myeloma.

Li Yin, Ashujit Tagde, Reddy Gali, Yu-Tzu Tai, Teru Hideshima, Kenneth Anderson, David Avigan, Donald Kufe,

Lenalidomide (LEN) acts directly on multiple myeloma (MM) cells by inducing cereblon-mediated degradation of interferon regulatory factor 4, Ikaros (IKZF)1 and IKZF3, transcription factors that are essential for MM cell survival. The mucin 1 (MUC1) C-terminal transmembrane subunit (MUC1-C) oncoprotein is aberrantly expressed by MM cells and protects against reactive ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2017, 178(6):914-926]

Cited: 4 times

View full text PDF listing >>



MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.

Hasan Rajabi, Donald Kufe,

The MUC1 gene evolved in mammalian species to provide protection of epithelia. The transmembrane MUC1 C-terminal subunit (MUC1-C) signals stress to the interior of the epithelial cell and, when overexpressed as in most carcinomas, functions as an oncoprotein. MUC1-C induces the epithelial-mesenchymal transition (EMT) by activating the inflammatory NF-κB p65 ... Read more >>

Biochim Biophys Acta Rev Cancer (Biochimica et biophysica acta. Reviews on cancer)
[2017, 1868(1):117-122]

Cited: 17 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1745 s